Basel Agonistes


The Basel Committee has gone to great lengths to avoid repeating that mistake. But by ham-fistedly prescribing and proscribing in equal measure, it has stitched together a monster that can’t clear the first hurdle: flexibility. Market advances have already outrun many of Basel II’s embedded assumptions about risk mitigation. Meanwhile, the Committee has looked out over markets for thriving risk-transfer techniques such as securitisation and decided (for reasons no-one has yet been able

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

If you already have an account, please sign in here.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here